Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00388726




Registration number
NCT00388726
Ethics application status
Date submitted
13/10/2006
Date registered
17/10/2006
Date last updated
7/01/2020

Titles & IDs
Public title
E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer
Scientific title
The "EMBRACE" Trial: Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389. A Phase III Open-Label, Randomized, Parallel, Two-arm, Multi-center Study of E7389 Versus "Treatment of Physician's Choice" in Patients With Locally Recurrent, Metastatic Breast Cancer, Previously Treated With At Least Two and a Maximum of Five Prior Chemotherapy Regimens, Including an Anthracycline and a Taxane
Secondary ID [1] 0 0
2006-001949-34
Secondary ID [2] 0 0
E7389-G000-305
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Breast Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Breast

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - E7389
Treatment: Drugs - Physician's Choice

Experimental: 1 -

Active comparator: 2 -


Treatment: Drugs: E7389
1.4 mg/m\^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days.

Treatment: Drugs: Physician's Choice
Treatment of the Physician's Choice defined as any single agent chemotherapy, hormonal treatment or biological therapy approved for the treatment of cancer; or palliative treatment or radiotherapy, administered according to local practice, if applicable.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Overall Survival
Timepoint [1] 0 0
From date of randomization until death from any cause
Secondary outcome [1] 0 0
Progression-Free Survival.
Timepoint [1] 0 0
Until disease progression or death.
Secondary outcome [2] 0 0
Best Overall Response
Timepoint [2] 0 0
Until Day 30 or every 3 months during Follow-up period for patients who complete study without PD.
Secondary outcome [3] 0 0
Duration of Response.
Timepoint [3] 0 0
From first documented CR or PR until disease progression or death.
Secondary outcome [4] 0 0
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Timepoint [4] 0 0
From start of study drug administration up to 30 days after the last dose of study drug (approximately up to 42 months)

Eligibility
Key inclusion criteria
1. Female patients with histologically or cytologically confirmed carcinoma of the breast.

Every effort should be made to make paraffin embedded tissue or slides from the diagnostic biopsy or surgical specimen available for confirmation of diagnosis.
2. Patients with locally recurrent or metastatic disease who have received at least two (and not more than five) prior chemotherapeutic regimens for breast cancer, at least two of which were administered for treatment of locally recurrent and/or metastatic disease.

Prior therapy must be documented by the following criteria prior to entry onto study:
* Regimens must have included an anthracycline (e.g., doxorubicin, epirubicin) and a taxane (e.g., paclitaxel, docetaxel) in any combination or order. Treatment with any of these agents is not required if they are contraindicated for a certain patient.
* One or two of these regimens may have been administered as adjuvant and/or neoadjuvant therapy, but at least 2 must have been given for relapsed or metastatic disease.
* Patients must have proved refractory to the most recent chemotherapy, documented by progression on or within six (6) months of therapy.
* Patients with Human Epidermal Growth Factor 2 (HER2/neu) positive tumors may additionally have been treated with trastuzumab.
* Patients may have additionally been treated with anti-hormonal therapy.
3. Resolution of all chemotherapy or radiation-related toxicities to Grade 1 severity or lower, except for stable sensory neuropathy <= Grade 2 and alopecia.
4. Age >= 18 years.
5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2.
6. Life expectancy of >= 3 months.
7. Adequate renal function as evidenced by serum creatinine <= 2.0 mg/dL or calculated creatinine clearance >= 40 mL/min per the Cockcroft and Gault formula.
8. Adequate bone marrow function as evidenced by absolute neutrophil count (ANC) >= 1.5 x 10^9/L, hemoglobin >= 10.0 g/dL (a hemoglobin <10.0 g/dL is acceptable if it is corrected by growth factor or transfusion), and platelet count >= 100 x 10^9/L.
9. Adequate liver function as evidenced by bilirubin <= 1.5 times the upper limits of normal (ULN) and alkaline phosphatase, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) <= 3 x ULN (in the case of liver metastases <= 5 x ULN), unless there are bone metastases, in which case liver specific alkaline phosphatase must be separated from the total and used to assess the liver function instead of the total alkaline phosphatase. In case alkaline phosphatase is >3 x ULN (in absence of liver metastases) or > 5 x ULN (in presence of liver metastases) AND patient is known to have bone metastases, the liver specific alkaline phosphatase must be separated from the total and used to assess the liver function instead of the total alkaline phosphatase.
10. Patients willing and able to comply with the study protocol for the duration of the study.
11. Written informed consent prior to any study-specific screening procedures with the understanding that the patient may withdraw consent at any time without prejudice.

EXCLUSION CRITERIA

1. Patients who have received any of the following treatments within the specified period before E7389 or TPC treatment start:

* chemotherapy, radiation, trastuzumab or hormonal therapy within three weeks.
* any investigational drug within four weeks.
2. Radiation therapy encompassing > 30% of marrow.
3. Prior treatment with mitomycin C or nitrosourea.
4. Pulmonary lymphangitic involvement that results in pulmonary dysfunction requiring active treatment, including the use of oxygen.
5. Patients with brain or subdural metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids for this indication for at least 4 weeks before starting treatment in this study. Any signs (e.g., radiologic) and/or symptoms of brain metastases must be stable for at least 4 weeks before starting study treatment; radiographic stability should be determined by comparing a contrast-enhanced computed tomography or magnetic resonance imaging brain scan performed during screening to a prior scan performed at least 4 weeks earlier.
6. Patients with meningeal carcinomatosis.
7. Patients who are receiving anti-coagulant therapy with warfarin or related compounds, other than for line patency, and cannot be changed to heparin-based therapy if randomized to E7389 are not eligible. If a patient is to continue on mini-dose warfarin, then the prothrombin time (PT) or international normalized ratio (INR) must be closely monitored.
8. Women who are pregnant or breast-feeding; women of childbearing potential with either a positive pregnancy test at screening or no pregnancy test; women of childbearing potential unless (1) surgically sterile or (2) using adequate measures of contraception in the opinion of the Investigator. Perimenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential.
9. Severe/uncontrolled intercurrent illness/infection.
10. Significant cardiovascular impairment (history of congestive heart failure > New York Heart Association grade II, unstable angina or myocardial infarction within the past six months, or serious cardiac arrhythmia).
11. Patients with organ allografts requiring immunosuppression.
12. Patients with known positive HIV status.
13. Patients who have had a prior malignancy, other than previous breast cancer, carcinoma in situ of the cervix, or non-melanoma skin cancer, unless the prior malignancy was diagnosed and definitively treated >= 5 years previously with no subsequent evidence of recurrence.
14. Patients with pre-existing neuropathy > Grade 2.
15. Patients with a hypersensitivity to halichondrin B and/or halichondrin B chemical derivative.
16. Patients who participated in a prior E7389 clinical trial whether or not E7389 was received.
17. Patients with other significant disease or disorders that, in the Investigator's opinion, would exclude the patient from the study.
Minimum age
18 Years
Maximum age
No limit
Sex
Females
Can healthy volunteers participate?
No
Key exclusion criteria

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/11/2006
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/06/2013
Sample size
Target
Accrual to date
Final
762
Recruitment in Australia
Recruitment state(s)
QLD,SA
Recruitment hospital [1] 0 0
The Queen Elizabeth Hospital - Southport
Recruitment hospital [2] 0 0
Servicio De Oncologia - Woodville South
Recruitment hospital [3] 0 0
Maroondah Breast Clinic - Melbourne
Recruitment hospital [4] 0 0
Mater Medical Centre - North Sydney
Recruitment hospital [5] 0 0
Mount Hospital - Perth
Recruitment hospital [6] 0 0
Royal Perth Hospital, Department of Medical Oncology - Perth
Recruitment postcode(s) [1] 0 0
4215 - Southport
Recruitment postcode(s) [2] 0 0
5011 - Woodville South
Recruitment postcode(s) [3] 0 0
3135 - Melbourne
Recruitment postcode(s) [4] 0 0
2060 - North Sydney
Recruitment postcode(s) [5] 0 0
6000 - Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Indiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Iowa
Country [9] 0 0
United States of America
State/province [9] 0 0
Louisiana
Country [10] 0 0
United States of America
State/province [10] 0 0
Michigan
Country [11] 0 0
United States of America
State/province [11] 0 0
Missouri
Country [12] 0 0
United States of America
State/province [12] 0 0
Montana
Country [13] 0 0
United States of America
State/province [13] 0 0
Nevada
Country [14] 0 0
United States of America
State/province [14] 0 0
New York
Country [15] 0 0
United States of America
State/province [15] 0 0
North Carolina
Country [16] 0 0
United States of America
State/province [16] 0 0
Oregon
Country [17] 0 0
United States of America
State/province [17] 0 0
Texas
Country [18] 0 0
United States of America
State/province [18] 0 0
Washington
Country [19] 0 0
Argentina
State/province [19] 0 0
Buenos Aires
Country [20] 0 0
Argentina
State/province [20] 0 0
Pcia. Santa Fe
Country [21] 0 0
Argentina
State/province [21] 0 0
San Miguel De Tucuman
Country [22] 0 0
Argentina
State/province [22] 0 0
Cordoba
Country [23] 0 0
Argentina
State/province [23] 0 0
Rosario Santa Fe
Country [24] 0 0
Argentina
State/province [24] 0 0
Santa Fe
Country [25] 0 0
Austria
State/province [25] 0 0
Graz Steiermark
Country [26] 0 0
Austria
State/province [26] 0 0
Salzburg
Country [27] 0 0
Belgium
State/province [27] 0 0
Brussels
Country [28] 0 0
Belgium
State/province [28] 0 0
Bruxelles
Country [29] 0 0
Belgium
State/province [29] 0 0
Charleroi
Country [30] 0 0
Belgium
State/province [30] 0 0
Gent
Country [31] 0 0
Belgium
State/province [31] 0 0
Kortrijk
Country [32] 0 0
Brazil
State/province [32] 0 0
CE
Country [33] 0 0
Brazil
State/province [33] 0 0
GO
Country [34] 0 0
Brazil
State/province [34] 0 0
PA
Country [35] 0 0
Brazil
State/province [35] 0 0
RJ
Country [36] 0 0
Brazil
State/province [36] 0 0
RS
Country [37] 0 0
Brazil
State/province [37] 0 0
SP
Country [38] 0 0
Canada
State/province [38] 0 0
Ontario
Country [39] 0 0
Canada
State/province [39] 0 0
Quebec
Country [40] 0 0
Croatia
State/province [40] 0 0
Osijek
Country [41] 0 0
Croatia
State/province [41] 0 0
Zagreb
Country [42] 0 0
Czechia
State/province [42] 0 0
Brno
Country [43] 0 0
Czechia
State/province [43] 0 0
Jihlava
Country [44] 0 0
Czechia
State/province [44] 0 0
Prague
Country [45] 0 0
Czechia
State/province [45] 0 0
Praha 10
Country [46] 0 0
Czechia
State/province [46] 0 0
Praha
Country [47] 0 0
France
State/province [47] 0 0
Agners Cedex 01
Country [48] 0 0
France
State/province [48] 0 0
Besancon
Country [49] 0 0
France
State/province [49] 0 0
Bordeaux
Country [50] 0 0
France
State/province [50] 0 0
Caen Cedex 05
Country [51] 0 0
France
State/province [51] 0 0
Clermont-Ferrand Cedex 01
Country [52] 0 0
France
State/province [52] 0 0
Dijon Cedex
Country [53] 0 0
France
State/province [53] 0 0
Lyon
Country [54] 0 0
France
State/province [54] 0 0
Paris
Country [55] 0 0
France
State/province [55] 0 0
Saint Brieuc Cedex
Country [56] 0 0
France
State/province [56] 0 0
Tours Cedex
Country [57] 0 0
Hungary
State/province [57] 0 0
Budapest
Country [58] 0 0
Hungary
State/province [58] 0 0
Debrecen
Country [59] 0 0
Hungary
State/province [59] 0 0
Pecs
Country [60] 0 0
Hungary
State/province [60] 0 0
Szombathely
Country [61] 0 0
Italy
State/province [61] 0 0
Firenze (FI)
Country [62] 0 0
Italy
State/province [62] 0 0
Genova
Country [63] 0 0
Italy
State/province [63] 0 0
Lecce (LE)
Country [64] 0 0
Italy
State/province [64] 0 0
Milano
Country [65] 0 0
Italy
State/province [65] 0 0
Roma
Country [66] 0 0
Italy
State/province [66] 0 0
Rozzano
Country [67] 0 0
Italy
State/province [67] 0 0
Sora
Country [68] 0 0
Poland
State/province [68] 0 0
Gdansk
Country [69] 0 0
Poland
State/province [69] 0 0
Gdynia
Country [70] 0 0
Poland
State/province [70] 0 0
Gilwice
Country [71] 0 0
Poland
State/province [71] 0 0
Krakow
Country [72] 0 0
Poland
State/province [72] 0 0
Poznan
Country [73] 0 0
Poland
State/province [73] 0 0
Szczecin
Country [74] 0 0
Poland
State/province [74] 0 0
Warszawa
Country [75] 0 0
Russian Federation
State/province [75] 0 0
Izhervsk Udmurtia
Country [76] 0 0
Russian Federation
State/province [76] 0 0
Kazan
Country [77] 0 0
Russian Federation
State/province [77] 0 0
Krasnodar
Country [78] 0 0
Russian Federation
State/province [78] 0 0
Moscow
Country [79] 0 0
Russian Federation
State/province [79] 0 0
Nizhny Novgorod
Country [80] 0 0
Russian Federation
State/province [80] 0 0
Novosibirisk
Country [81] 0 0
Russian Federation
State/province [81] 0 0
Petrozavodsk
Country [82] 0 0
Russian Federation
State/province [82] 0 0
Pyatigorsk
Country [83] 0 0
Russian Federation
State/province [83] 0 0
St Petersburg
Country [84] 0 0
Russian Federation
State/province [84] 0 0
St. Petersburg
Country [85] 0 0
Russian Federation
State/province [85] 0 0
Tomsk
Country [86] 0 0
Russian Federation
State/province [86] 0 0
Yaroslavl
Country [87] 0 0
South Africa
State/province [87] 0 0
Cape Town
Country [88] 0 0
South Africa
State/province [88] 0 0
Eastern Cape
Country [89] 0 0
South Africa
State/province [89] 0 0
Johannesburg
Country [90] 0 0
South Africa
State/province [90] 0 0
Pretoria
Country [91] 0 0
Spain
State/province [91] 0 0
Barcelona
Country [92] 0 0
Spain
State/province [92] 0 0
Gerona
Country [93] 0 0
Spain
State/province [93] 0 0
Jaen
Country [94] 0 0
Spain
State/province [94] 0 0
Salamanca
Country [95] 0 0
Spain
State/province [95] 0 0
Santa Cruz de Tenerife
Country [96] 0 0
Spain
State/province [96] 0 0
Sevilla
Country [97] 0 0
Spain
State/province [97] 0 0
Zanagoza
Country [98] 0 0
Switzerland
State/province [98] 0 0
Aarau
Country [99] 0 0
Switzerland
State/province [99] 0 0
Bern Bern
Country [100] 0 0
Switzerland
State/province [100] 0 0
St. Gallen
Country [101] 0 0
Switzerland
State/province [101] 0 0
Thun
Country [102] 0 0
Switzerland
State/province [102] 0 0
Winterhur

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Eisai Inc.
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Eisai Limited
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results are available at https://clinicaltrials.gov/study/NCT00388726